Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin.56(2), 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• Herrero R, Castellsague X, Pawlita M et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J. Natl Cancer Inst.95(23), 1772–1783 (2003).
   PubMed Web of Science ®Google Scholar
• Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int. J. Cancer114(5), 806–816 (2005).
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Atasoy BM, Daley FM et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J. Clin. Oncol.23(24), 5560–5567 (2005).
   PubMed Web of Science ®Google Scholar
• Bentzen SM. Repopulation in radiation oncology: perspectives of clinical research. Int. J. Radiat. Biol.79(7), 581–585 (2003).
   PubMed Web of Science ®Google Scholar
• Elkind MM. The initial part of the survival curve: does it predict the outcome of fractionated radiotherapy? Radiat. Res.114(3), 425–436 (1988).
   PubMed Web of Science ®Google Scholar
• Bourhis J, Amand C, Pignon J. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head and Neck Cancer) database focused on concomitant chemoradiotherapy. J. Clin. Oncol.22(14 Suppl.), 5505 (2004).
   Google Scholar
• Kufe D. In: Cancer Medicine, 6th Edition. Decker BC (Ed.). Hamilton, ON, Canada 2v (2003).
   Google Scholar
• Calais G, Alfonsi M, Bardet E et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J. Natl Cancer Inst.91(24), 2081–2086 (1999).
   PubMed Web of Science ®Google Scholar
• Brizel DM, Albers ME, Fisher SR et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med.338(25), 1798–1804 (1998).
   PubMed Web of Science ®Google Scholar
• Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet355(9208), 949–955 (2000).
   PubMed Web of Science ®Google Scholar
• Adelstein DJ, Li Y, Adams GL et al. An intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol.21(1), 92–98 (2003).
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med.349(22), 2091–2098 (2003).
   PubMed Web of Science ®Google Scholar
• Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med.350(19), 1945–1952 (2004).
   PubMed Web of Science ®Google Scholar
• Laramore GE, Scott CB, al-Sarraf M et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int. J. Radiat. Oncol. Biol. Phys.23(4), 705–713 (1992).
   PubMed Web of Science ®Google Scholar
• Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol.23(11), 2445–2459 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transduction pathways in colorectal cancer – more than skin deep. J. Clin. Oncol.23(23), 5374–5385 (2005).
   PubMed Web of Science ®Google Scholar
• Venook AP. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer103(12), 2435–2446 (2005).
   PubMed Web of Science ®Google Scholar
• Johnson BE, Janne PA. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res.65(17), 7525–7529 (2005).
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Belani CP. Molecularly-targeted therapies for non-small cell lung cancer. Expert Opin. Pharmacother.6(15), 2667–2679 (2005).
   PubMed Web of Science ®Google Scholar
• Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer78(6), 1284–1292 (1996).
   PubMed Web of Science ®Google Scholar
• Rubin Grandis J, Melhem MF, Gooding WE et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl Cancer Inst.90(11), 824–832 (1998).
   PubMed Web of Science ®Google Scholar
• Cohen S. The stimulation of epidermal proliferation by a specific protein (EGF). Dev. Biol.12(3), 394–407 (1965).
   PubMed Web of Science ®Google Scholar
• Cohen S, Carpenter G, King L Jr. Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J. Biol. Chem.255(10), 4834–4842 (1980).
   PubMed Web of Science ®Google Scholar
• Ushiro H, Cohen S. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J. Biol. Chem.255(18), 8363–8365 (1980).
   PubMed Web of Science ®Google Scholar
• Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res.44(3), 1002–1007 (1984).
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. Growth factor receptors as targets for antitumor therapy with monoclonal antibodies. Prog. Allergy45147–45160 (1988).
   Google Scholar
• Downward J, Yarden Y, Mayes E et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature307(5951), 521–527 (1984).
   PubMed Web of Science ®Google Scholar
• Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res.53(18), 4322–4328 (1993).
   PubMed Web of Science ®Google Scholar
• Baselga J, Norton L, Masui H et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl Cancer Inst.85(16), 1327–1333 (1993).
   PubMed Web of Science ®Google Scholar
• Balaban N, Moni J, Shannon M, Dang L, Murphy E, Goldkorn T. The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochim. Biophys. Acta1314(1–2), 147–156 (1996).
   PubMed Web of Science ®Google Scholar
• Schmidt-Ullrich RK, Mikkelsen RB, Dent P et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene15(10), 1191–1197 (1997).
   PubMed Web of Science ®Google Scholar
• Sheridan MT, O'Dwyer T, Seymour CB, Mothersill CE. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat. Oncol. Investig.5(4), 180–186 (1997).
   PubMedGoogle Scholar
• Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin. Cancer Res.5(10), 2884–2890 (1999).
   PubMed Web of Science ®Google Scholar
• Saleh MN, Raisch KP, Stackhouse MA et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFR antibody C225 and radiation. Cancer Biother. Radiopharm.14(6), 451–463 (1999).
   PubMed Web of Science ®Google Scholar
• Milas L, Fan Z, Andratschke NH, Ang KK. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int. J. Radiat. Oncol. Biol. Phys.58(3), 966–971 (2004).
   PubMed Web of Science ®Google Scholar
• Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res.59(8), 1935–1940 (1999).
   PubMed Web of Science ®Google Scholar
• Milas L, Mason K, Hunter N et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res.6(2), 701–708 (2000).
   PubMed Web of Science ®Google Scholar
• Harari PM, Huang S. Radiation combined with EGFR signal inhibitors: head and neck cancer focus. Semin. Radiat. Oncol.16(1), 38–44 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int. J. Radiat. Oncol. Biol. Phys.58(2), 344–352 (2004).
   PubMed Web of Science ®Google Scholar
• Dassonville O, Formento JL, Francoual M et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J. Clin. Oncol.11(10), 1873–1878 (1993).
   PubMed Web of Science ®Google Scholar
• Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res.62(24), 7350–7356 (2002).
   PubMed Web of Science ®Google Scholar
• Vanhoefer U, Tewes M, Rojo F et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol.22(1), 175–184 (2004).
   PubMed Web of Science ®Google Scholar
• Crombet T, Osorio M, Cruz T et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J. Clin. Oncol.22(9), 1646–1654 (2004).
   PubMed Web of Science ®Google Scholar
• Tyagi P. Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer. Clin. Colorectal Cancer5(1), 21–23 (2005).
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood99(3), 754–758 (2002).
   PubMed Web of Science ®Google Scholar
• Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol.21(21), 3940–3947 (2003).
   PubMed Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell7(4), 301–311 (2005).
   PubMed Web of Science ®Google Scholar
• Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell5(4), 317–328 (2004).
   PubMed Web of Science ®Google Scholar
• Sigismund S, Woelk T, Puri C et al. Clathrin-independent endocytosis of ubiquitinated cargos. Proc. Natl Acad. Sci. USA102(8), 2760–2765 (2005).
   PubMed Web of Science ®Google Scholar
• Puri C, Tosoni D, Comai R et al. Relationships between EGFR signaling-competent and endocytosis-competent membrane microdomains. Mol. Biol. Cell16(6), 2704–2718 (2005).
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med.354(6), 567–578 (2006).
   PubMed Web of Science ®Google Scholar
• Robert F, Ezekiel MP, Spencer SA et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol.19(13), 3234–3243 (2001).
   PubMed Web of Science ®Google Scholar
• Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol.18(4), 904–914 (2000).
   PubMed Web of Science ®Google Scholar
• Shin DM, Donato NJ, Perez-Soler R et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res.7(5), 1204–1213 (2001).
   PubMed Web of Science ®Google Scholar
• Bonner JA, Raisch KP, Trummell HQ et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J. Clin. Oncol.18(Suppl. 1), S47–S53 (2000).
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J et al. Cetuximab improves locoregional control and survival of locoregionally advanced head and neck cancer: independent review of mature data with a median followup of 45 months. AACR-NCI-EORTC International Conference. Mol. Targets Cancer Ther. Clin. Cancer Res.11(24 Pt 2), S9058 (2005).
   Google Scholar
• Geisler SA, Olshan AF, Weissler MC et al. p16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin. Cancer Res.8(11), 3445–3453 (2002).
   PubMed Web of Science ®Google Scholar
• Pfister DG, Su YB, Kraus DH et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot Phase II study of a new combined-modality paradigm. J. Clin. Oncol.24(7), 1072–1078 (2006).
   PubMed Web of Science ®Google Scholar
• Diaz E, Sturgis E, Laramore G, Sabichi A, Lippman S, Clayman G. Neoplasms of the head and neck. In: Cancer Medicine, 6th Edition. Kufe D, Bast R Jr, Hait W (Eds). 21325–21371 (2003).
   Google Scholar
• Benchalal M, Bachaud JM, Francois P et al. Hyperfractionation in the reirradiation of head and neck cancers. Result of a pilot study. Radiother. Oncol36(3), 203–210 (1995).
   PubMed Web of Science ®Google Scholar
• Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol.24(17), 2659–2665 (2006).
   PubMed Web of Science ®Google Scholar
• Trigo R, Hitt P, Koralewski E et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a Phase II study. ASCO Annual Meeting (2004).
   Google Scholar
• Saltz LB, Lenz H, Hochster H et al. Randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. ASCO Annual Meeting (2005).
   Google Scholar
• Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351(4), 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Baselga J, Trigo JM, Bourhis J et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol.23(24), 5568–5577 (2005).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Arquette M, Shin DM et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol.23(24), 5578–5587 (2005).
   PubMed Web of Science ®Google Scholar
• Vermorken J. Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies. J. Clin. Oncol.23(16 Suppl.), 5505 (2005).
   Google Scholar
• Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol.23(34), 8646–8654 (2005).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Vega-Villegas ME, Remenar E, Hitt R, Kawecki A. Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol.24(18 Suppl.), 5537 (2006).
   Google Scholar
• Bier H, Hoffmann T, Haas I, van Lierop A. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol. Immunother.46(3), 167–173 (1998).
   PubMed Web of Science ®Google Scholar
• Trarbach T, Schleucher N, Weber D et al. Phase I study of the humanized anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with cisplatin, 5-fluorouracil and leucovorin (PFL) in patients (pts) with advanced esophago-gastric (EG) adenocarcinoma. J. Clin. Oncol.23(16 Suppl.), 3156 (2005).
   PubMed Web of Science ®Google Scholar
• Panousis C, Rayzman VM, Johns TG et al. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2–7 EGFR or amplified EGFR. Br. J. Cancer92(6), 1069–1077 (2005).
   PubMed Web of Science ®Google Scholar
• Jungbluth AA, Stockert E, Huang HJ et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc. Natl Acad. Sci. USA100(2), 639–644 (2003).
   PubMed Web of Science ®Google Scholar
• Erlichman C, Hidalgo M, Boni JP et al. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol.24(15), 2252–2260 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen F, Stadler WM et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol.21(10), 1980–1987 (2003).
   PubMed Web of Science ®Google Scholar
• Kirby AM, A’Hern RP, D’Ambrosio C et al. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br. J. Cancer94(5), 631–636 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen EE, Kane MA, List MA et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin. Cancer Res.11(23), 8418–8424 (2005).
   PubMed Web of Science ®Google Scholar
• Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol.22(1), 77–85 (2004).
   PubMed Web of Science ®Google Scholar
• Belon J, Irigoyen A, Rodriguez I et al. Preliminary results of a Phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck. J. Clin. Oncol.23(16 Suppl.), 5563 (2005).
   Web of Science ®Google Scholar
• Kim ES, Kies M, Sabichi A et al. Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). J. Clin. Oncol.23(16 Suppl.), 5546 (2005).
   Google Scholar
• Wirth LJ, Haddad RI, Lindeman NI et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol.23(28), 6976–6981 (2005).
   PubMed Web of Science ®Google Scholar
• Dragnev KH, Petty WJ, Shah S et al. Bexarotene and erlotinib for aerodigestive tract cancer. J. Clin. Oncol.23(34), 8757–8764 (2005).
   PubMed Web of Science ®Google Scholar
• Callender T, el-Naggar AK, Lee MS, Frankenthaler R, Luna MA, Batsakis JG. PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer74(1), 152–158 (1994).
   PubMed Web of Science ®Google Scholar
• Rhys-Evans P, Modjtahedi H, Eccles SA, O’Charoenrat P. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin. Exp. Metastasis18(2), 155–161 (2000).
   PubMed Web of Science ®Google Scholar
• Vokes EE, Cohen EEW, Mauer AM et al. A Phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J. Clin. Oncol.23(16 Suppl.), 5504 (2005).
   Google Scholar
• Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res.64(15), 5355–5362 (2004).
   PubMed Web of Science ®Google Scholar
• Matar P, Rojo F, Cassia R et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin. Cancer Res.10(19), 6487–6501 (2004).
   PubMed Web of Science ®Google Scholar
• Cohen EE, Haraf DJ, Stenson KM et al. Integration of gefitinib (G), into a concurrent chemoradiation (CRT) regimen followed by G adjuvant therapy in patients with locally advanced head and neck cancer (HNC) – a Phase II Trial. ASCO Annual Meeting Proceedings (2005).
   Google Scholar
• Herchenhorn D, Dias FL, Araujo CM et al. Phase I/II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol.23(16 Suppl.), 5596 (2005).
   Google Scholar
• Doss H, Greco F, Meluch A et al. Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: a Phase I/II trial of the Minnie Pearl Cancer Research Network. ASCO Annual Meeting Proceedings24(18S), S290 (2006).
   Google Scholar
• Savvides P, Agarwala S, Greskovich J et al. Phase I study of the EGFR tyrosine kinase inhibitor erlobtinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). ASCO Annual Meeting Proceedings24(18S), S291 (2006).
   Google Scholar
• Burris HA III, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol.23(23), 5305–5313 (2005).
   PubMed Web of Science ®Google Scholar
• Spector NL, Xia W, Burris H III et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol.23(11), 2502–2512 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen EE, Lingen MW, Martin LE et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin. Cancer Res.11(22), 8105–8108 (2005).
   PubMed Web of Science ®Google Scholar
• Herrington KJ, Bourhis J, Nutting CM, Rosine D, Theodosiou AM, Gardiner S. A Phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol.24(18 Suppl.), 5553 (2006).
   Google Scholar
• Abidoye OO, Cohen EE, Wong SJ et al. A Phase II study of lapatinb in recurrent/metastatic squamous carcinoma of the head and neck. J. Clin. Oncol.24(18 Suppl.), 5568 (2006).
   Google Scholar
• Ryan AJ, Wedge SR. ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br. J. Cancer92(Suppl. 1), S6–S13 (2005).
   PubMed Web of Science ®Google Scholar
• Traxler P, Allegrini PR, Brandt R et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res.64(14), 4931–4941 (2004).
   PubMed Web of Science ®Google Scholar
• Fujii M, Yamashita T, Ishiguro R, Tashiro M, Kameyama K. Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris Nasus Larynx29(2), 175–181 (2002).
   PubMed Web of Science ®Google Scholar
• Chua DT, Nicholls JM, Sham JS, Au GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.59(1), 11–20 (2004).
   PubMed Web of Science ®Google Scholar
• Tao Y, Song X, Deng X et al. Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by Epstein-Barr-encoded oncoprotein latent membrane protein 1. Exp. Cell Res.303(2), 240–251 (2005).
   PubMed Web of Science ®Google Scholar
• Stevenson D, Charalambous C, Wilson JB. Epstein-Barr virus latent membrane protein 1 (CAO) up-regulates VEGF and TGF α concomitant with hyperlasia, with subsequent up-regulation of p16 and MMP9. Cancer Res.65(19), 8826–8835 (2005).
   PubMed Web of Science ®Google Scholar
• Hsu CH, Gao M, Chen CL, Yeh PY, Cheng AL. Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro. Oncology68(4–6), 538–547 (2005).
   PubMed Web of Science ®Google Scholar
• Tao YG, Tan YN, Liu YP et al. Epstein-Barr virus latent membrane protein 1 modulates epidermal growth factor receptor promoter activity in a nuclear factor κB-dependent manner. Cell Signal.16(7), 781–790 (2004).
   PubMed Web of Science ®Google Scholar
• Chan AT, Hsu MM, Goh BC et al. Multicenter, Phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J. Clin. Oncol.23(15), 3568–3576 (2005).
   PubMed Web of Science ®Google Scholar
• Lee SC, Lim SG, Soo R et al. Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. Pharmacogenet. Genomics16(1), 73–74 (2006).
   PubMed Web of Science ®Google Scholar
• Vered M, Braunstein E, Buchner A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck24(7), 632–636 (2002).
   PubMed Web of Science ®Google Scholar
• Glisson BS, Blumenschein G, Francisco M, Erasmus J, Zinner R, Kies M. Phase II trial of gefitinib in patients with incurable salivary gland cancer. ASCO Annual Meeting (2005).
   Google Scholar
• Agulnik M, Cohen EE, Cohen RB et al. A Phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) or non-ACC malignant tumors of the salivary gland. J. Clin. Oncol.24(18 Suppl.), 5566 (2006).
   Google Scholar
• Licitra L, Locati L, Potepan P et al. Cetuximab (C225) in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): a monoinstitutional Phase II study. ASCO Annual Meeting Proceedings24(18 Suppl.), S291 (2006).
   Google Scholar
• Ensinger C, Spizzo G, Moser P et al. Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann. NY Acad. Sci.103069–103077 (2004).
   Google Scholar
• Schiff BA, McMurphy AB, Jasser SA et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin. Cancer Res.10(24), 8594–8602 (2004).
   PubMed Web of Science ®Google Scholar
• Nobuhara Y, Onoda N, Yamashita Y et al. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br. J. Cancer92(6), 1110–1116 (2005).
   PubMed Web of Science ®Google Scholar
• Kim S, Prichard CN, Younes MN et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin. Cancer Res.12(2), 600–607 (2006).
   PubMed Web of Science ®Google Scholar
• Holting T, Siperstein AE, Clark OH, Duh QY. Epidermal growth factor (EGF)- and transforming growth factor α – stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur. J. Endocrinol.132(2), 229–235 (1995).
   PubMed Web of Science ®Google Scholar
• Gabler B, Aicher T, Heiss P, Senekowitsch-Schmidtke R. Growth inhibition of human papillary thyroid carcinoma cells and multicellular spheroids by anti-EGF-receptor antibody. Anticancer Res.17(4B), 3157–3159 (1997).
   PubMed Web of Science ®Google Scholar
• Wells S, You Y, Lakhani V et al. A Phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. ASCO Annual Meeting Proceedings24(18S), S288 (2006).
   Google Scholar
• Milas L, Mason KA, Ang KK. Epidermal growth factor receptor and its inhibition in radiotherapy: in vivo findings. Int. J. Radiat. Biol.79(7), 539–545 (2003).
   PubMed Web of Science ®Google Scholar
• Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J. Histochem. Cytochem.52(7), 893–901 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson GA, Mannel R, Khalifa M et al. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. Gynecol. Oncol.65(3), 425–429 (1997).
   PubMed Web of Science ®Google Scholar
• Haber DA, Bell D, Sordella R, Lynch T, Settleman J. Activating mutations in the epidermal growth factor receptor underlie responsiveness of non-small cell lung cancer to the tyrosine kinase inhibitor Gefitinib. Presented at: Am. Assoc. Cancer Res. 96th Annual Meeting, April 17 (2005).
   Google Scholar
• Price DK, Figg WD. Mutations in the EGFR: the importance of genotyping. Cancer Biol. Ther.3(5), 434–435 (2004).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol.23(11), 2556–2568 (2005).
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA101(36), 13306–13311 (2004).
   PubMed Web of Science ®Google Scholar
• Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur. J. Cancer42(1), 109–111 (2006).
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol.23(11), 2556–2568 (2005).
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304(5676), 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Willmore-Payne C, Holden JA, Layfield LJ. Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod. Pathol.19(5), 634–640 (2006).
   PubMed Web of Science ®Google Scholar
• Lee JW, Soung YH, Kim SY et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin. Cancer Res.11(8), 2879–2882 (2005).
   PubMed Web of Science ®Google Scholar
• Amador ML, Oppenheimer D, Perea S et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res.64(24), 9139–9143 (2004).
   PubMed Web of Science ®Google Scholar
• Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol.6(5), 279–286 (2005).
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, McCoy J et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J. Clin. Oncol.23(28), 6838–6845 (2005).
   PubMed Web of Science ®Google Scholar
• Gordon AN, Finkler N, Edwards RP et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a Phase II multicenter study. Int. J. Gynecol. Cancer15(5), 785–792 (2005).
   PubMed Web of Science ®Google Scholar
• Tang PA, Tsao MS, Moore MJ. A review of erlotinib and its clinical use. Expert Opin. Pharmacother.7(2), 177–193 (2006).
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol.23(22), 5235–5246 (2005).
   PubMed Web of Science ®Google Scholar